UBE2O acts downstream of the interleukin-1 pathway to regulate MLL/COMPASS stability Stabilizing wild-type MLL protein inhibits MLL leukemia cell proliferation UBE2O and IRAK inhibition alters a common set of MLL chimera target genes Targeting the IL-1 pathway is a potential therapeutic strategy for MLL leukemia